The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.
Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...
New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and ...
Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation ...
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...
4don MSN
We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...
Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.
We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...
Some prominent healthcare and consumer stocks have fallen out of favor with the market, so now is the time to pounce on some great deals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback